EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Cancer co‐medication quality in older patients with polypharmacy: A large randomized trial testing a medication review versus usual care

Miriam Degen iD, Annette Kopp-Schneider iD, Tomislav Vlaski iD, Sigrid Carlsson iD, Peter Hallermann, Ludmilla Jewlanowa, Jana Barinoff, Valentin Goede, Christian Lüders iD, Thomas Kiefer-Trendelenburg iD, Diana Lüftner, Jasmin Doll und 4 weitere

Journal of Internal Medicine · 2026-12 · 300 (6) · 802-820

DOI: 10.1111/joim.70161 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Internal Medicine, online erschienen am 23.09.2026. Verfasst von Miriam Degen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Polypharmacy, Neoplasms, Medication Review. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Aid,, Deutsche Krebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence from randomized controlled trials (RCTs) testing medication reviews in geriatric oncology is sparse.

Methods

We conducted a single‐blinded RCT in ten rehabilitation clinics across Germany. Patients with common cancers, aged ≥ 65 years, and polypharmacy (regularly ≥ five drugs) were randomly allocated in equal proportions to usual care or a comprehensive pharmacist‐led medication review conducted with the validated Fit fOR The Aged (FORTA) list. The FORTA score is the sum of drugs classified as potentially inappropriate medication (PIM) (each two points), drug underuse (each one point), and drug overuse (each one point). Changes in the FORTA score and its subcomponents from rehabilitation admission to discharge were tested using the chi‐square test or the Wilcoxon's rank‐sum test.

Findings

At admission, 66.1%, 94.6%, and 58.9% of 443 trial participants included in the intention‐to‐treat analysis were exposed to PIM, medication underuse, or overuse, respectively, and the median FORTA score was six. At discharge, participants of the intervention group ( n = 234) had a statistically significant greater reduction in the mean FORTA score than the control group ( n = 209): mean difference [95% confidence interval]: −3.7 [−4.2; −3.3] score points. Furthermore, the proportions of subjects with PIM, underuse, and overuse were statistically significantly reduced by the intervention by 41.3, 35.5, and 30.7 percentage points (all p < 0.001).

Interpretation

The pharmacist‐led intervention with the FORTA list substantially improved the medication quality of older cancer patients with polypharmacy in clinical practice. A reduction of four FORTA score points (rounded) translates, for example, to the withdrawal of two PIMs or four drugs labeled overuse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PolypharmacyNeoplasmsMedication ReviewHumansAgedFemaleSingle-Blind MethodMaleAged, 80 and overInappropriate PrescribingPotentially Inappropriate Medication ListGermany

Stichwörter der Autor:innen

cancergeriatricsinternal medicinemedication reviewquality of healthcare

Autor:innen und Institutionen

  • Division of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Faculty of Medicine, University of Heidelberg, Heidelberg, Germany.
  • Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Translational Medicine, Division of Urological Cancers, Lund University, Lund, Sweden.
  • Clinic Niederrhein, Bad Neuenahr-Ahrweiler, Germany.
  • Rehabilitation Centre Ückeritz/Clinic Ostseeblick, Ückeritz, Germany.

ORCID-Profile: Miriam Degen, Annette Kopp-Schneider, Tomislav Vlaski, Sigrid Carlsson, Christian Lüders, Thomas Kiefer-Trendelenburg, Jürgen Wagner, Hermann Brenner, Ben Schöttker

Förderung

  • German Cancer Aid,
  • Deutsche Krebshilfe

Zitieren

APA

Degen, M., Kopp-Schneider, A., Vlaski, T., Carlsson, S., Hallermann, P., Jewlanowa, L., Barinoff, J., Goede, V., Lüders, C., Kiefer-Trendelenburg, T., Lüftner, D., Doll, J., Wagner, J., Leibbrand, B., Brenner, H., & Schöttker, B. (2026). Cancer co‐medication quality in older patients with polypharmacy: A large randomized trial testing a medication review versus usual care. Journal of Internal Medicine, 300(6), 802-820. https://doi.org/10.1111/joim.70161

Vancouver

Degen M, Kopp-Schneider A, Vlaski T, Carlsson S, Hallermann P, Jewlanowa L, et al. Cancer co‐medication quality in older patients with polypharmacy: A large randomized trial testing a medication review versus usual care. Journal of Internal Medicine. 2026;300(6):802-820. doi:10.1111/joim.70161

BibTeX
@article{Degen2026,
  author = {Degen, Miriam and Kopp-Schneider, Annette and Vlaski, Tomislav and Carlsson, Sigrid and Hallermann, Peter and Jewlanowa, Ludmilla and Barinoff, Jana and Goede, Valentin and Lüders, Christian and Kiefer-Trendelenburg, Thomas and Lüftner, Diana and Doll, Jasmin and Wagner, Jürgen and Leibbrand, Birgit and Brenner, Hermann and Schöttker, Ben},
  title = {Cancer co‐medication quality in older patients with polypharmacy: A large randomized trial testing a medication review versus usual care},
  journal = {Journal of Internal Medicine},
  year = {2026},
  volume = {300},
  number = {6},
  pages = {802--820},
  doi = {10.1111/joim.70161}
}
Kostenlos starten →